Newsfeeds - Spark Newswire

1 minute read

Vir Biotechnology Gets Price Targets Cuts By Analysts After Q4 Results

Today, 10:31 PM

Vir Biotechnology, Inc. (NASDAQ: VIR) reported worse-than-expected Q4 results. Vir Biotechnology posted a Q4 loss of $0.76 per share, versus market expectations of $0.39 per share. The company’s quarterly sales came in at $49.41 million, versus estimates of $97.30 million.

VIR

17 minute read

Earnings

Earnings Scheduled For February 23, 2023

By Benzinga Insights

Today, 10:31 PM

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.

AAOI

4 minute read

Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

Today, 10:31 PM

Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023.

AKAN

2 minute read

DraftKings To Rally Around 38%? Here Are 10 Other Analyst Forecasts For Tuesday

By Lisa Levin

Today, 10:31 PM

Wells Fargo boosted the price target for Deere & Company (NYSE: DE) from $485 to $510. Wells Fargo analyst Seth Weber maintained an Overweight rating on the stock. Deere shares fell 0.5% to $431.08 in pre-market trading.

ADSK

1 minute read

Goldman Sachs Upgrades Vir Biotechnology to Buy, Raises Price Target to $53

By Benzinga Newsdesk

Today, 10:31 PM

Goldman Sachs analyst Paul Choi upgrades Vir Biotechnology (NASDAQ:VIR) from Neutral to Buy and raises the price target from $41 to $53.

VIR

1 minute read

Morgan Stanley Upgrades Vir Biotechnology to Equal-Weight, Raises Price Target to $30

By Benzinga Newsdesk

Today, 10:31 PM

Morgan Stanley analyst Michael Ulz upgrades Vir Biotechnology (NASDAQ:VIR) from Underweight to Equal-Weight and raises the price target from $18 to $30.

VIR

1 minute read

European Official Says COVID-19 Booster Uptake Disappointing In The Region

By Vandana Singh

Today, 10:31 PM

Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather disappointing." The European average rate of receiving booster doses was only 29% in the groups considered to be at the highest risk.

AZN

2 minute read

After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade

By Robert Kuczmarski

Today, 10:31 PM

Bill Gates has two portfolios he makes trades from: the Bill & Melinda Gates Foundation and the Bill & Melinda Gates Foundation Trust.

BCEL

8 minute read

Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday

By Lisa Levin

Today, 10:31 PM

Gainers

4 minute read

Events
News

Vir Biotechnology Presenting New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection at AASLD Liver Meeting

By Charles Gross

Today, 10:31 PM

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B virus (HBV) portfolio aimed at achieving a functional cure.

VIR